Welcome to LookChem.com Sign In|Join Free
  • or
C7H7BrN2OS is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1404480-07-4

Post Buying Request

1404480-07-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1404480-07-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1404480-07-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,4,4,8 and 0 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1404480-07:
(9*1)+(8*4)+(7*0)+(6*4)+(5*4)+(4*8)+(3*0)+(2*0)+(1*7)=124
124 % 10 = 4
So 1404480-07-4 is a valid CAS Registry Number.

1404480-07-4Downstream Products

1404480-07-4Relevant academic research and scientific papers

Enhanced treatment regimens using mTor inhibitors

-

Page/Page column 116; 117, (2015/11/27)

The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.

COMBINATION OF KINASE INHIBITORS AND USES THEREOF

-

, (2014/10/04)

The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3 -kinase α and/or mTOR in a subject.

COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

-

, (2014/12/09)

The present invention provides for methods and pharmaceutical compositions for treating proliferative disorders. In one aspect, the method comprises administration of two cell-cycle suppressors having a synergistic effect. In another aspect, two cell-cycle suppressors having a synergistic effect are provided in a pharmaceutical composition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1404480-07-4